epidermal growth factor


Also found in: Dictionary, Thesaurus, Medical, Legal, Financial, Acronyms, Wikipedia.

epidermal growth factor

[‚ep·ə¦dərm·əl ′grōth ‚fak·tər]
(physiology)
A polypeptide produced in animals that stimulates and sustains the replication of epidermal cells (of ectodermal or endodermal origin); its human equivalent is urogastrone.
References in periodicals archive ?
In addition, epidermal growth factor can enhance the appearance of solar purpura.
A combined approach of inhibiting both the hormones and the epidermal growth factor receptor may be beneficial for some women in treating hormone-dependent breast cancer.
Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system.
Role of arachidonic acid metabolism in the mitogenic response of Balb/c 3t3 fibroblasts to epidermal growth factor.
Differing targets and etfiect s of keratinocyte growth factor, platelet-derived growth factor-BB, epidermal growth factor, and neu differentiation factor.
Comment: Tarceva targets the human epidermal growth factor receptor (HER1 or EGFR) pathway, which is "critical" to cell growth in NSCLC and other cancers, according to Genentech.
Anchorage-independent transformation has been observed in clone 41 cells treated with TPA, epidermal growth factor (EGF), tumor necrosis factor alpha (TNF[alpha]) (5), and other tumor promoters (6).
Tarceva is a small molecule designed to target the human epidermal growth factor receptor 1 (HER1) pathway, one of the factors critical to cell growth in non-small cell lung cancer (NSCLC) and other solid tumors.
EGFR encodes a molecule that acts as a docking station on cell surfaces for a protein called epidermal growth factor (EGF).
To refurbish the cell layer, the researchers gave patients massive doses of the human gut peptide called epidermal growth factor (EGF).
Hana Biosciences (NASDAQ:HNAB), a biopharmaceutical company focused on advancing cancer care, today announced that it has acquired exclusive rights to develop and commercialize Menadione, a preclinical product candidate for the prevention and treatment of skin rash associated with the use of epidermal growth factor receptor (EGFR) inhibitors in New York.

Full browser ?